Inhibition of Interleukin-3 Reversed the Inflammatory Response and Organ Damage Induced by Sepsis
qi wu,Jingjing Wang,Bi Sheng,Yu Cai,Yu Zhang,Huajun wu,Wanjuan xiong,Fang Dong,Shouzhi Fu,Shuping Deng,Yonggang Chen,Jinhu Wu,Xiong Wang
DOI: https://doi.org/10.2139/ssrn.4361233
2023-01-01
Abstract:Background: Sepsis is mainly characterized by a dysregulated host response to infection and cytokine storm syndrome is one of the main pathogenic mechanisms of sepsis. Interleukin-3 (IL-3), a pro-inflammatory factor, has a multifaceted role in inflammatory diseases. However, its role in the pathogenesis of sepsis remains unknown.Methods: Serum levels of IL-3 were measured and analyzed in 38 Intensive Care Unit (ICU) patients with sepsis, 36 non-septic ICU patient controls, and 30 healthy volunteers. The effects of IL-3 on survival, inflammation, tissue damage, bacterial clearance, and the MAPK pathway were assessed using 2 male mouse models: cecum puncture and ligation (CLP)-induced sepsis and lipopolysaccharide (LPS)-induced sepsis.Results: Serum IL-3 levels were significantly higher in patients with sepsis on the day of diagnosis compared to ICU patient controls and healthy volunteers. Patients with septic shock showed significantly higher serum IL-3 levels compared to non-shocked patients. Serum interleukin-3 levels were correlated with sequential (sepsis-related) organ failure assessment scores (SOFA). Serum IL-3 level could discriminate septic shock from sepsis. Anti-IL-3 antibodies prolong survival time, recombinant IL-3 shortens survival time in two mouse models of CLP-induced sepsis and LPS-induced sepsis. Anti-IL-3 antibody application reduced inflammatory factor release (including IL-3, Interleukin-6 (IL-6), Interleukin1-β (IL-1β), and Tumor necrosis factor-α(TNF-α)); attenuated organ damage (including lung, liver, and kidney); enhanced bacterial clearance; attenuated splenic tissue inflammatory factor (including IL-3, IL-6, IL-1β, and TNF-α) protein content; and down-regulated phosphorylated p38, ERK, JNK protein content in MAPK pathway in lung, liver, and kidney. Recombinant IL-3 application promotes the release of inflammatory factors (including IL-3, IL-6, IL-1β, and TNF-α); exacerbates organ damage (including lung, liver, and kidney); reduces bacterial clearance; increases inflammatory factors (including IL-3, IL-6, IL-1-β, and TNF-α) protein content in splenic tissues; upregulates phosphorylated p38, ERK, JNK protein content in MAPK pathway in lung, liver, and kidney.Conclusions: Serum IL-3 levels are elevated in patients with sepsis, which may correlate with the severity of the disease. In experimental sepsis, we demonstrated that inhibition of IL-3 prolongs survival time, whereas IL-3 plays the opposite role. Anti-IL-3 may be a new target for sepsis treatment.